Functional Alterations to the Nigrostriatal System in Mice Lacking All Three Members of the Synuclein Family

The synucleins (α, β, and γ) are highly homologous proteins thought to play a role in regulating neurotransmission and are found abundantly in presynaptic terminals. To overcome functional overlap between synuclein proteins and to understand their role in presynaptic signaling from mesostriatal dopaminergic neurons, we produced mice lacking all three members of the synuclein family. The effect on the mesostriatal system was assessed in adult (4- to 14-month-old) animals using a combination of behavioral, biochemical, histological, and electrochemical techniques. Adult triple-synuclein-null (TKO) mice displayed no overt phenotype and no change in the number of midbrain dopaminergic neurons. TKO mice were hyperactive in novel environments and exhibited elevated evoked release of dopamine in the striatum detected with fast-scan cyclic voltammetry. Elevated dopamine release was specific to the dorsal not ventral striatum and was accompanied by a decrease of dopamine tissue content. We confirmed a normal synaptic ultrastructure and a normal abundance of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein complexes in the dorsal striatum. Treatment of TKO animals with drugs affecting dopamine metabolism revealed normal rate of synthesis, enhanced turnover, and reduced presynaptic striatal dopamine stores. Our data uniquely reveal the importance of the synuclein proteins in regulating neurotransmitter release from specific populations of midbrain dopamine neurons through mechanisms that differ from those reported in other neurons. The finding that the complete loss of synucleins leads to changes in dopamine handling by presynaptic terminals specifically in those regions preferentially vulnerable in Parkinson's disease may ultimately inform on the selectivity of the disease process.

[1]  John Sharkey,et al.  Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice , 2004 .

[2]  A. Davies,et al.  Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene , 2003, Molecular and Cellular Biology.

[3]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  H. Tanila,et al.  Role of alpha-synuclein in presynaptic dopamine recruitment. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  S. Cragg,et al.  α-Synuclein and dopamine at the crossroads of Parkinson's disease , 2010, Trends in Neurosciences.

[6]  S. Cragg,et al.  Increased striatal dopamine release and hyperdopaminergic‐like behaviour in mice lacking both alpha‐synuclein and gamma‐synuclein , 2008, The European journal of neuroscience.

[7]  M. Zigmond,et al.  A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[9]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[10]  A. Davies,et al.  Persyn, a Member of the Synuclein Family, Has a Distinct Pattern of Expression in the Developing Nervous System , 1998, The Journal of Neuroscience.

[11]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[12]  A. Björklund,et al.  Dopamine neuron systems in the brain: an update , 2007, Trends in Neurosciences.

[13]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[14]  Jochen Roeper,et al.  Individual dopamine midbrain neurons: Functional diversity and flexibility in health and disease , 2008, Brain Research Reviews.

[15]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[16]  Masahiko Watanabe,et al.  Calbindin 1, fibroblast growth factor 20, and α-synuclein in sporadic Parkinson’s disease , 2008, Human Genetics.

[17]  J. Schwartz,et al.  Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum , 1976, Psychopharmacology.

[18]  J. Trojanowski,et al.  Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. , 2002, Neurotoxicology.

[19]  S. Cragg,et al.  α6-Containing Nicotinic Acetylcholine Receptors Dominate the Nicotine Control of Dopamine Neurotransmission in Nucleus Accumbens , 2008, Neuropsychopharmacology.

[20]  S. Cragg,et al.  Dopamine Release and Uptake Dynamics within Nonhuman Primate Striatum In Vitro , 2000, The Journal of Neuroscience.

[21]  J. Bolam,et al.  A Dopaminergic Axon Lattice in the Striatum and Its Relationship with Cortical and Thalamic Terminals , 2008, The Journal of Neuroscience.

[22]  A. Sidhu,et al.  Attenuation of dopamine transporter activity by alpha-synuclein. , 2003, Neuroscience letters.

[23]  K. Channon,et al.  The effect of α‐synuclein knockdown on MPP+ toxicity in models of human neurons , 2008, The European journal of neuroscience.

[24]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[25]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[26]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[27]  B. Ghetti,et al.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. , 2010, Brain : a journal of neurology.

[28]  R. Wightman,et al.  Profound neuronal plasticity in response to inactivation of the dopamine transporter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[30]  J. Davis,et al.  Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in Vivo using an inhibitor of the aromatic amino acid decarboxylase , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  V. Buchman,et al.  Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. , 2004, Journal of neurochemistry.

[32]  P. Chan,et al.  Silencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells , 2008, Neurochemical Research.

[33]  Erica L. Unger,et al.  Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice , 2006, Neurobiology of Disease.

[34]  T. Hastings,et al.  Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells , 2006, Journal of neurochemistry.

[35]  V. Buchman,et al.  γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein , 2009, Human molecular genetics.

[36]  A. Sidhu,et al.  Attenuation of dopamine transporter activity by α-synuclein , 2003, Neuroscience Letters.

[37]  S. Chandra,et al.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.

[38]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[39]  V. Buchman,et al.  Edinburgh Research Explorer Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice , 2010 .

[40]  Leonidas Stefanis,et al.  α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis , 2006, The Journal of Neuroscience.

[41]  Helmut L. Haas,et al.  Functional diversity of ventral midbrain dopamine and GABAergic neurons , 2004, Molecular Neurobiology.

[42]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[43]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[44]  Heikki Tanila,et al.  Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein , 2005, Neurobiology of Disease.

[45]  J. Broman,et al.  Different basal levels of CaMKII phosphorylated at Thr286/287 at nociceptive and low‐threshold primary afferent synapses , 2005, The European journal of neuroscience.

[46]  Giuseppe Battaglia,et al.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Hawkins,et al.  α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.

[48]  S. Cragg,et al.  Nicotine amplifies reward-related dopamine signals in striatum , 2004, Nature Neuroscience.

[49]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[50]  H. Tanila,et al.  Role of α-Synuclein in Presynaptic Dopamine Recruitment , 2004, The Journal of Neuroscience.

[51]  S. Cragg Variable Dopamine Release Probability and Short-Term Plasticity between Functional Domains of the Primate Striatum , 2003, The Journal of Neuroscience.

[52]  R. Hen,et al.  Hyperactivity and impaired response habituation in hyperdopaminergic mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[54]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[55]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[56]  E. Masliah,et al.  A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration , 2010, The Journal of Neuroscience.

[57]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.